8-K: Cadrenal Therapeutics Appoints Interim CFO, Signs New Services Agreement

Cadrenal Therapeutics, Inc. has appointed John P. Sharp as Interim Chief Financial Officer and entered into a new Scope of Work with Lohman & Associates, Inc. for financial consulting services.

Summary

• Cadrenal Therapeutics, Inc. announced the appointment of John P. Sharp as Interim Chief Financial Officer, effective June 25, 2026.
• In connection with this appointment, Quang X. Pham has ceased to serve as the Company's Interim Chief Financial Officer.
• The Company has entered into Scope of Work Number Five (SOW5) with Lohman & Associates, Inc. (L&A) for Mr. Sharp to provide services as Interim CFO, Principal Financial Officer, and Principal Accounting Officer.
• This SOW5 is governed by a Master Services Agreement (MSA) dated August 21, 2024, under which L&A provides accounting, business strategy, consulting, and fractional CFO services.
• Mr. Sharp will provide up to 24 hours of service per week at a rate of $455 per hour, with a $25,000 retainer applied to the final invoice for SOW5.
• Steven Zelenkofske resigned from the Board of Directors, effective June 30, 2026.
• Dr. Glynn Wilson was realigned from a Class I director to a Class III director and reappointed to the Audit Committee, Nominating and Corporate Governance Committee, and appointed to the Compensation Committee.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily detailing routine operational and governance changes rather than significant strategic shifts or financial performance indicators.

Positives

• Appointment of an experienced Interim CFO with over 30 years of financial and business planning experience, including extensive CFO roles in biopharmaceutical companies.
• Continuation of financial consulting services through a Master Services Agreement with Lohman & Associates, Inc., ensuring ongoing support for financial operations and compliance.
• Clear definition of services and fees for the Interim CFO role, including a maximum weekly hour limit and hourly rate, providing cost predictability.
• Board director realignment and committee appointments aim to optimize governance structure.

Negatives

• The departure of Steven Zelenkofske from the Board of Directors, although stated as not due to disagreement, represents a change in board composition.
• The need for an interim CFO suggests a potential gap or transition in permanent financial leadership.

Risks

• Reliance on a fractional CFO service provider (L&A) may present challenges in terms of full-time dedication compared to a permanent hire.
• The company is actively searching for a permanent CFO, indicating that the current interim arrangement is not a long-term solution.
• Potential for increased costs if services exceed the agreed-upon 24 hours per week or require out-of-scope work.
• The resignation of a board member could be perceived negatively by investors, even if no disagreement is cited.

Future Outlook

The Company is actively conducting a search for a permanent Chief Financial Officer. Dr. Glynn Wilson's appointment to committees and his service term are defined.

Management Comments

• Mr. Sharp, age 61, is a seasoned finance executive with more than 30 years of experience in financial and business planning and currently serves as a Senior Director at Lohman & Associates.
• Mr. Sharp has served as Chief Financial Officer for several biopharmaceutical companies since April 2007.
• Mr. Zelenkofskes resignation was not the result of any disagreement with the Company regarding any matter relating to the Companys operations, policies, or practices.

Industry Context

StockSavvy.ai notes that the appointment of an experienced interim CFO, particularly from a specialized consulting firm like Lohman & Associates, is a common strategy for biopharmaceutical companies navigating complex financial reporting and compliance requirements, especially during periods of transition or growth.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of an experienced interim CFO and board adjustments are standard corporate actions that aim to maintain operational and governance stability. The search for a permanent CFO may signal a focus on strengthening financial leadership.
• Employees: The transition of CFO responsibilities and board changes may create a period of adjustment. The ongoing services agreement with L&A ensures continued support for finance functions.
• Creditors/Suppliers: The continued engagement of financial consulting services suggests a commitment to managing financial obligations and operations effectively.

Next Steps

• Cadrenal Therapeutics, Inc. will continue its search for a permanent Chief Financial Officer.
• John P. Sharp will provide interim CFO services as outlined in SOW5.
• Dr. Glynn Wilson will continue to serve on the Board and its committees until the 2028 annual meeting.

Key Dates

Keywords

Interim CFO Appointment, Master Services Agreement, Lohman & Associates, Cadrenal Therapeutics, Finance Consulting, Board of Directors, SEC Reporting, Financial Compliance, John P. Sharp, Steven Zelenkofske, Glynn Wilson